- 1、Shi, M, Guo, Y, Xu, J, Yan, L, Li, X, Liu, R, Feng, Y, Zhang, Y, Zhao, Y, Zhang, C, Du, K, Li, M, Zhang, Y, Zhang, J, Li, Z, Ren, D, Liu, P. Gaudichaudione H ameliorates liver fibrosis and inflammation by targeting NRF2 signaling pathway. FREE RADICAL BIO MED. 2024-11-01; 224 770-784. doi: 10.1016/j.freeradbiomed.2024.09.020 IF:7.1 Q1 .
- 2、Dai, D., Dong, C., Yan, Q., Sun, Y., Zhang, C., Li, Z., Xu, S, (2024). I2U-Net: A dual-path U-Net with rich information interaction for medical image segmentation. MED IMAGE ANAL, 97 103241. https://doi.org/10.1016/j.media.2024.103241 IF: 10.7 Q1 .
- 3、Zeng, K., Huang, N., Liu, N., Deng, X., Mu, Y., Zhang, X., Zhang, J., Zhang, C., Li, Y., Li, Z, (2024). LACTB suppresses liver cancer progression through regulation of ferroptosis. Redox Biol, 75 103270. https://doi.org/10.1016/j.redox.2024.103270IF: 10.7 Q1.
- 4、Dong, C., Dai, D., Li, Z., Xu, S, (2024). A novel deep network with triangular-star spatial-spectral fusion encoding and entropy-aware double decoding for coronary artery segmentation INFORM FUSION, 102561. https://doi.org/10.1016/j.inffus.2024.102561IF: 14.7 Q1.
- 5、Liu, X., Sun, Y., Su, Y., Gao, Y., Zhang, T., Wang, Q., Zhang, X., Zhang, D., Sun, C., Li, J., Li, Z., Zhang, B, (2024). The compensatory role of T cells from lymph nodes in mice with splenectomy. J CELL MOL MED, 28 (10), e18363. https://doi.org/10.1111/jcmm.18363IF: 4.3 Q2.
- 6、Zhou, L., Jiang, M., Duan, R., Zuo, F., Li, Z., Xu, S, (2024). Barriers and Implications of 5G Technology Adoption for Hospitals in Western China: Integrated Interpretive Structural Modeling and Decision-Making Trial and Evaluation Laboratory Analysis. JMIR Mhealth Uhealth, 12 e48842. https://doi.org/10.2196/48842IF: 5.4 Q1.
- 7、Sun, J., Li, Y., Bie, B., Tian, H., Li, J., Yang, L., Zhou, Z., Mu, Y., Li, Z, (2024). Dystrobrevin beta is a promising prognostic biomarker and therapeutic target for hepatocellular carcinoma. Am J Transl Res, 16 (10), 6072-6096. https://doi.org/10.62347/FCFO5076IF: 1.7 Q3.
- 8、Guihu, W., Wei, D., Hailong, Z., Chongyu, Z., Jin, S., Mengchen, Z., Jian, Z., Rui, Z., Song, R., Chen, Z., Xi, L., Zongfang, L., An, J, (2024). Activation of MEK-ERK-c-MYC signaling pathway promotes splenic M2-like macrophage polarization to inhibit PHcH-liver cirrhosis. Front Immunol, 15 1417521. https://doi.org/10.3389/fimmu.2024.1417521IF: 5.7 Q1.
- 9、Liu, N., Wang, Q., Zhu, P., He, G., Li, Z., Chen, T., Yuan, J., La, T., Tian, H., Li, Z, (2024). DHX34 as a promising biomarker for prognosis, immunotherapy and chemotherapy in Pan-Cancer: A Comprehensive Analysis and Experimental Validation. J Cancer, 15 (20), 6594-6615. https://doi.org/10.7150/jca.102230IF: 3.3 Q2.
- 10、Sun, J., Li, Y., Tian, H., Chen, H., Li, J., Li, Z, (2024). Comprehensive analysis identifies long non-coding RNA RNASEH1-AS1 as a potential prognostic biomarker and oncogenic target in hepatocellular carcinoma. Am J Cancer Res, 14 (3), 996-1014. https://doi.org/10.62347/JPHF4071IF: 3.6 Q2.
- 12、Liu, H., Huang, Y., Li, Z., Han, S., Liu, T., Zhao, Q, (2024). An innovative gene expression modulating strategy by converting nucleic acids into HNC therapeutics using carrier-free nanoparticles. Front Immunol, 14 1343428. https://doi.org/10.3389/fimmu.2023.1343428 IF: 5.7 Q1
- 13、Li, M., Wang, Y., Liu, R., Shi, M., Zhao, Y., Zeng, K., Fu, R., Liu, P, (2023). Fluoride exposure confers NRF2 activation in hepatocyte through both canonical and non-canonical signaling pathways. ENVIRON TOXICOL, 39 (1), 252-263. https://doi.org/10.1002/tox.23954， IF: 4.4 Q1.
- 14、Feng, Y., Shi, M., Zhang, Y., Li, X., Yan, L., Xu, J., Liu, C., Li, M., Bai, F., Yuan, F., Sun, Y., Liu, R., Zhao, Y., Yang, L., Zhang, Y., Guo, Y., Zhang, J., Zhou, R., Liu, P, (2024). Protocatechuic acid relieves ferroptosis in hepatic lipotoxicity and steatosis via regulating NRF2 signaling pathway. CELL BIOL TOXICOL, 40 (1), 104. https://doi.org/10.1007/s10565-024-09953-7，IF: 5.3 Q1.
- 15、Li, X., Xu, J., Yan, L., Tang, S., Zhang, Y., Shi, M., Liu, P, (2024). Targeting Disulfidptosis with Potentially Bioactive Natural Products in Metabolic Cancer Therapy. Metabolites, 14 (11), https://doi.org/10.3390/metabo14110604，IF: 3.4 Q2
